DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405

Information source: Hanmi Pharmaceutical Company Limited
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension(HTN)

Intervention: HGP0904 (Drug); HGP0608 (Drug); HGP1405 (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Hanmi Pharmaceutical Company Limited

Summary

The purpose of this study is to investigate the pharmacokinetic interaction and safety between HGP0904, HGP0608 and HGP1405 when administered alone and in combination in healthy male volunteers

Clinical Details

Official title: A Randomized, Open-label, 4-way Crossover Single Dose Clinical Trial to Investigate the Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 When Administered Alone and in Combination in Healthy Male Volunteers

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome:

AUClast

Cmax

Secondary outcome:

AUCinf

Tmax

T1/2

CL/F

Vz/F

Eligibility

Minimum age: 19 Years. Maximum age: 45 Years. Gender(s): Male.

Criteria:

Inclusion Criteria:

- 19~45 years old

- Healthy men

Exclusion Criteria:

- Gastroentestinal disease affecting drug absorption

Locations and Contacts

Seoul National University Bundang Hospital, Bundang, Gyeonggi, Korea, Republic of
Additional Information

Starting date: August 2014
Last updated: June 11, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017